A Phase 4 interventional study of Venlafaxine 37.5 MG and Placebo in Acute Pain, Chronic Pain and Knee Pain Chronic, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Acute Pain with a site in United States — 49 open to participants now, 55 under way, 1 of them phase 3. Acute Pain · United States.
Among the 353 studies in Acute Pain with a site in United States, this one is the 140th largest by enrollment of the 322 interventional ones that give a count, is one of 31 that started in 2021, is one of 66 in phase 4, and was the 241st registered.
1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.
Browse Acute Pain studies →49 of the 353 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Aponia Laboratories, Inc. · Sites in United States, Germany
Ages 18–65
Florida State University · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–40
Ochsner Health System · Sites in United States
Ages 35+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 65 · Phase 3 48 · Phase 4 66
First in 2001; this study’s year is marked. 31 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 86 across 905 interventional studies indexed under Acute Pain.
Median enrollment 86 across the 322 interventional studies, 100 across the 31 observational. Of the 265 that completed or were terminated, 133 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 353 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 6 studies filed under Acute Pain — fewer than ten, so there is no comparison to draw.
32 of the studies in Acute Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07930559Phase 3Aponia Laboratories, Inc.Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | 2027-06 |
| NCT07511816Eli Lilly and CompanyA Study of LY4515100 in Participants With Pain Following Third Molar Removal | 2026-11 |
| NCT05335070Rutgers, The State University of New JerseyReducing Pain From Wisdom Molar Extractions | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
| NCT05458037Women and Infants Hospital of Rhode IslandRCT of Pain Perception With Fast and Slow Tenaculum Application | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 353 studies in Acute Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients experience pain after their knee replacement surgery - and some may continue to experience persistent pain long after their knee replacement surgery. Traditional pain management strategies reply on pain medication such as opioids for pain control. However, these drugs do not work well for pain associated with movement or the the nerve pain (tingling, electrical sensations) after surgery. In addition, opioids are associated with significant side effects such as nausea, vomiting, respiratory depression, depression, cognitive dysfunction and risk of persistent opioid use. Neuropathic pain medications, such as venlafaxine are effective in managing nerve pain. Recent studies also support its potential role in acute pain management. Here, we propose a prospective randomized clinical trial 1) to evaluate the efficacy of Venlafaxine in reducing pain intensity and opioid consumption at post-operative day 1 (POD1) and 1- week after surgery, and 2) to examine whether the use of Venlafaxine will reduce the incidents of chronic postsurgical pain in TKA patients at 3-month time point.
Patients meeting the inclusion criteria will be randomized to receive either Venlafaxine extended release (ER) 37.5 mg/d or a placebo on the day of surgery and continue the treatment for 7 days after surgery. The primary outcomes include pain severity score (numeric rating scale, NRS) and consumption of morphine miligram equivalent (MME) at 24 hours. The secondary outcome will measure MME and NRS at postoperative day 7. In addition, the disability scale and perceived function 3 months after surgery will be compared to the baseline level by using PROMIS (Patient-Reported Outcomes Measurement Information System)10 Global Health, KOOS, JR. (Knee injury and Osteoarthritis Outcome Score Short Form), and VR-12 (Veterans RAND 12 Item Health Survey) Scale.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in placebo arm will receive inactive placebo capsule daily for 7 consecutive days starting on day of primary arthroplasty surgery.
Drug: Placebo
Subjects in venlafaxine arm will receive venlafaxine 37.5mg daily for 7 consecutive days starting on day of primary arthroplasty surgery.
Drug: Venlafaxine 37.5 MG
venlafaxine 37.5mg daily for 7 consecutive days.
Also known as: SNRI analgesia
placebo filled pill daily for 7 consecutive days.
Also known as: control
Total Opioid Consumption on Postoperative Day 1
Total opioid consumption measured in morphine milligram equivalents (MME) on postoperative day 1.
Time frame: Postoperative Day 1
NRS Pain Score at Postoperative Day 1
Pain Scores will be measured on the Numerical Rating Scale (NRS), the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain.
Time frame: Postoperative Day 1
BPI Pain Interference Score at Postoperative Day 7
The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.
Time frame: Postoperative Day 7
Pain Severity and Interference at 3 Months Post Operatively
The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.
Time frame: 3 months
Opioid Consumption at 7 Days Postoperatively
morphine miligram equivalent
Time frame: 7 days
Functionality at 3 Months - KOOS Short Form
Knee Injury and Osteoarthritis Outcome Score Short Form (KOOS-12), a 12-item patient-reported questionnaire assessing knee-related quality of life. Scored 0-100 where 0 = extreme knee problems and 100 = no knee problems. Higher scores represent better knee function. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.
Time frame: 3 months
Number of Participants Consuming Opioids at 3 Months
number of participants who reported consuming opioids at the 3-month follow-up.
Time frame: 3 months
Patient Satisfaction With Pain Control
Patient satisfaction with pain control measured on a 0-100 visual analog scale, where 0 = completely dissatisfied and 100 = completely satisfied. Assessed at POD1, POD2, POD7, and 3 months postoperatively. Values represent model-predicted means from mixed-effects repeated measures analysis.
Time frame: Postoperative Days 1, 2, 7, and 3 months
Functionality at 3 Months - PROMIS Global-10
PROMIS Global-10 (Patient-Reported Outcomes Measurement Information System), reported as T-scores standardized to the US general population (mean=50, SD=10). Four subscores reported separately: Global Mental Health (GMH), Global Physical Health (GPH), Mental Component Score (MCS), and Physical Component Score (PCS). For all subscores, higher T-scores represent better health outcomes. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.
Time frame: 3 months
From May 2021 to March 2025, 408 patients were assessed for eligibility at UCSF Medical Center. Of these, 308 were excluded for not meeting inclusion criteria or declining to participate. One hundred patients provided informed consent and were randomized: 49 to venlafaxine and 51 to placebo.
| Milestone | Placebo | Venlafaxine |
|---|---|---|
| Started | 39 | 40 |
| Completed | 39 | 40 |
| Not completed | 0 | 0 |
Total opioid consumption measured in morphine milligram equivalents (MME) on postoperative day 1.
| mg MME | Placebo | Venlafaxine |
|---|---|---|
| Total Opioid Consumption on Postoperative Day 1 | 32.15 ± 30.30 | 23.60 ± 20.44 |
Pain Scores will be measured on the Numerical Rating Scale (NRS), the score ranges from 0-10, zero indicating no pain and 10 indicating the worst pain.
| Score (0-10) | Placebo | Venlafaxine |
|---|---|---|
| NRS Pain Score at Postoperative Day 1 | 3.5 ± 2.3 | 3.3 ± 2.1 |
The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.
| Score (0-10) | Placebo | Venlafaxine |
|---|---|---|
| BPI Pain Interference Score at Postoperative Day 7 | 3.5 ± 2.1 | 3.2 ± 2.0 |
The Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning.The BPI scale defines pain as follows:1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain.
| Score (0-10) | Placebo | Venlafaxine |
|---|---|---|
| Pain Severity and Interference at 3 Months Post Operatively | 1.5 ± 2.2 | 0.9 ± 1.6 |
morphine miligram equivalent
| morphine milligram equivalents (MME) | Placebo | Venlafaxine |
|---|---|---|
| Opioid Consumption at 7 Days Postoperatively | 33.67 (22.48 to 42.57) | 18.65 (9.84 to 27.46) |
Knee Injury and Osteoarthritis Outcome Score Short Form (KOOS-12), a 12-item patient-reported questionnaire assessing knee-related quality of life. Scored 0-100 where 0 = extreme knee problems and 100 = no knee problems. Higher scores represent better knee function. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.
| score change from baseline | Placebo | Venlafaxine |
|---|---|---|
| Functionality at 3 Months - KOOS Short Form | 16.3 ± 13.8 | 22.9 ± 17.5 |
number of participants who reported consuming opioids at the 3-month follow-up.
| Number of patients | Placebo | Venlafaxine |
|---|---|---|
| Number of Participants Consuming Opioids at 3 Months | 2 | 1 |
Patient satisfaction with pain control measured on a 0-100 visual analog scale, where 0 = completely dissatisfied and 100 = completely satisfied. Assessed at POD1, POD2, POD7, and 3 months postoperatively. Values represent model-predicted means from mixed-effects repeated measures analysis.
| score (0-100 VAS) | Placebo | Venlafaxine |
|---|---|---|
| Satisfaction score with Pain Control on POD1 | 78.6 (71.2 to 86.0) | 80.8 (73.2 to 88.5) |
| Satisfaction score with Pain Control on POD2 | 59.1 (51.8 to 66.4) | 69.8 (62.4 to 77.2) |
| Satisfaction score with Pain Control on POD7 | 61.0 (53.6 to 68.3) | 74.6 (67.3 to 82.0) |
| Satisfaction score with Pain Control at 3 months | 74.1 (66.5 to 81.7) | 89.6 (81.5 to 97.6) |
PROMIS Global-10 (Patient-Reported Outcomes Measurement Information System), reported as T-scores standardized to the US general population (mean=50, SD=10). Four subscores reported separately: Global Mental Health (GMH), Global Physical Health (GPH), Mental Component Score (MCS), and Physical Component Score (PCS). For all subscores, higher T-scores represent better health outcomes. Values reported as change from baseline to 3 months postoperatively (3-month score minus baseline score); higher change scores indicate greater improvement. Assessed at baseline and 3 months postoperatively.
| T-score | Placebo | Venlafaxine |
|---|---|---|
| PROMIS GMH change | 0.9 ± 7.1 | 3.6 ± 5.2 |
| PROMIS GPH change | 5.7 ± 7.1 | 7.5 ± 6.0 |
| PROMIS MCS change | -1.6 ± 9.7 | -0.2 ± 8.4 |
| PROMIS PCS change | 8.3 ± 10.0 | 11.9 ± 10.2 |
Collected over From first dose of study medication through postoperative day 7 (duration of study drug administration). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/38 (0%) | 0/38 (0%) | 0/38 (0%) |
| Venlafaxine | 0/39 (0%) | 0/39 (0%) | 0/39 (0%) |
Per-protocol population of 79 patients who received the allocated intervention and underwent primary total knee arthroplasty (40 venlafaxine, 39 placebo).
| Age, Continuous(Years) | Placebo | Venlafaxine | Total |
|---|---|---|---|
| Mean | 67.0 ± 6.7 | 66 ± 9.9 | 66.5 ± 8.3 |
| Sex: Female, Male(Participants) | Placebo | Venlafaxine | Total |
|---|---|---|---|
| Female | 22 | 19 | 41 |
| Male | 17 | 21 | 38 |
| Race and Ethnicity Not Collected(Participants) | Placebo | Venlafaxine | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Placebo | Venlafaxine | Total |
|---|---|---|---|
| United States | 39 | 40 | 79 |
| Body Mass Index (BMI)(kg/m²) | Placebo | Venlafaxine | Total |
|---|---|---|---|
| Mean | 28.5 ± 5.6 | 29.4 ± 4.1 | 29.0 ± 4.9 |
| Baseline NRS Pain Score(Score (0-10)) | Placebo | Venlafaxine | Total |
|---|---|---|---|
| Mean | 3.7 ± 2.2 | 4.1 ± 1.8 | 3.9 ± 2.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will share our raw clinical data with other researchers.
Supporting information: Study protocol
Time frame: For the entire study period
Access criteria: Non-profit and research purpose.
Ran from May 2021 to primary completion in Feb 2025, 45 months.
Results were first posted in Nov 2026, 1 year 8 months after primary completion.
Of 79 non-industry phase 4 interventional studies under Acute Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 32. This study's 45 months is above that.
Counting every sponsor, half of 84 studies reached it within 19 months; a quarter within 9 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venlafaxine
University of California, San Francisco →